Award notice Supplies
Antineoplastische geneesmiddelen (ATC L01)
Notice published in Dutch. The AI analysis summarises it for you in your language.
- Public buyer
- Healthcare Public Procurement (HeCaPP)
Saint-Gilles\Sint-Gillis - Place of performance
- 1020 Bruxelles\Brussel, Brussels-Capital
- Amount awarded
- €1,025,849 excl. VAT
- Planned end of contract
- 21 April 2030
likely re-tender around October 2029 - Bids received
- 2
- Procedure
- Open procedure
Any company may submit a bid. - Publication
- 24 April 2026
- Notice language
- Dutch
AI analysis: go for it or not?
Summary in English, criteria, documents to provide and a GO / NO GO verdict in one minute.
Unlimited analyses during the 14-day Pro trial, no card needed.
Description
Médicaments antinéoplasiques (ATC L01)
Awarded to
7 lots
- Paclitaxel 6mg/mL (voie intraveineuse)
- Pemetrexed 25mg/mL (voie intraveineuse)
- Témozolomide (voie orale)
- Docétaxel 20mg/mL (voie intraveineuse)
- Carboplatine 10mg/mL (voie intraveineuse)
- Gemcitabine (voie intraveineuse)
- Oxaliplatine 5mg/mL (voie intraveineuse)
CPV codes
European codes that classify what the contract is about. They are how we find the tenders for your trade.
33600000
Winning prices for comparable contracts
- A quarter below
- €269,390
- Median
- €449,863
- A quarter above
- €962,736
Amounts awarded (excl. VAT) over the last 3 years for 58 contracts in the same CPV group (3360…), excluding framework agreements. Half of the contracts fall between the two quartiles. TED source: mostly contracts above the EU thresholds, so amounts tend to be high.
Similar contracts already awarded
Source : TED – Office des publications de l'Union européenne © Union européenne, données retraitées. Reference 280788-2026.